
Endo International plc ENDP
Annual report 2023
added 03-06-2024
Endo International plc Accounts Payables 2011-2026 | ENDP
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Endo International plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.7 M | 109 M | 123 M | 94.4 M | 102 M | 96 M | 85.3 M | 127 M | 344 M | 308 M | 263 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 344 M | 85.3 M | 159 M |
Quarterly Accounts Payables Endo International plc
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90.9 M | 87.9 M | 96.7 M | 109 M | 85 M | 90.6 M | 101 M | 123 M | 111 M | 104 M | 105 M | 94.4 M | 94.4 M | 94.4 M | 94.4 M | 102 M | 102 M | 102 M | 102 M | 96 M | 96 M | 96 M | 96 M | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 127 M | 306 M | 318 M | 303 M | 348 M | 372 M | 348 M | 348 M | 294 M | 297 M | 297 M | 297 M | 251 M | 263 M | 263 M | 263 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 372 M | 85 M | 170 M |
Accounts Payables of other stocks in the Drug manufacturers industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
544 K | - | 7.5 % | $ 6.35 M | ||
|
Aerie Pharmaceuticals
AERI
|
8.28 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
9.57 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.94 M | - | 0.86 % | $ 117 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
13.9 M | $ 4.1 | 0.99 % | $ 57.6 M | ||
|
Catalent
CTLT
|
361 M | - | - | $ 11.5 B | ||
|
Alimera Sciences
ALIM
|
8.25 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
33.7 M | - | -23.39 % | $ 1.76 M | ||
|
DURECT Corporation
DRRX
|
1.78 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
19 M | - | -39.89 % | $ 27.7 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
7.33 M | - | - | $ 2.06 B | ||
|
Bausch Health Companies
BHC
|
719 M | $ 5.69 | 1.16 % | $ 2.08 B | ||
|
Jupiter Wellness
JUPW
|
2.48 M | - | - | $ 33.6 M | ||
|
Canopy Growth Corporation
CGC
|
26.1 M | $ 1.18 | -0.41 % | $ 127 M | ||
|
Harrow Health
HROW
|
35.4 M | $ 39.61 | -0.23 % | $ 1.46 B | ||
|
Lannett Company
LCI
|
29.7 M | - | 1.15 % | $ 7.11 M | ||
|
Solid Biosciences
SLDB
|
3.22 M | $ 7.96 | 0.51 % | $ 697 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
953 K | $ 1.12 | -1.67 % | $ 1.39 M | ||
|
Tilray
TLRY
|
70.8 M | $ 6.79 | 0.52 % | $ 4.2 B | ||
|
Organogenesis Holdings
ORGO
|
28.9 M | $ 2.38 | 1.49 % | $ 313 M | ||
|
Evolus
EOLS
|
23.4 M | $ 5.4 | 1.85 % | $ 348 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 8.16 | 1.68 % | $ 418 M | ||
|
Veru
VERU
|
3.04 M | $ 2.42 | 2.98 % | $ 326 M | ||
|
Pacira BioSciences
PCRX
|
19.1 M | $ 24.79 | 1.14 % | $ 1.15 B | ||
|
Viatris
VTRS
|
1.77 B | $ 14.74 | 0.99 % | $ 17.7 B | ||
|
Neoleukin Therapeutics
NLTX
|
1.95 M | - | - | $ 193 M | ||
|
ProPhase Labs
PRPH
|
5.9 M | - | - | $ 5.07 M | ||
|
cbdMD
YCBD
|
1.54 M | $ 1.01 | 0.5 % | $ 4.36 M | ||
|
Radius Health
RDUS
|
17.6 M | - | - | $ 1.42 B | ||
|
Assertio Holdings
ASRT
|
9.01 M | $ 18.07 | 0.17 % | $ 116 M | ||
|
PetIQ
PETQ
|
139 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
1.57 M | $ 7.45 | 3.33 % | $ 294 M | ||
|
Recro Pharma
REPH
|
1.31 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
3.89 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
2.22 M | $ 1.04 | 1.96 % | $ 51.9 M | ||
|
Zomedica Corp.
ZOM
|
1.72 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
1.94 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
2 M | $ 0.86 | -1.46 % | $ 30.9 M | ||
|
Tricida
TCDA
|
10 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
891 K | $ 0.63 | - | $ 2.7 M | ||
|
TherapeuticsMD
TXMD
|
377 K | $ 2.16 | -1.37 % | $ 25 M |